Merck: positive opinion from CHMP in adenocarcinoma (GEJ)
(CercleFinance.com) - Merck today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending approval of Keytruda, in combination with fluoropyrimidine and platinum-containing chemotherapy, as first-line treatment for locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in adults whose tumors express PD-L1.
The CHMP recommendation will now be considered by the European Commission for marketing authorisation in the European Union. A final decision is expected soon - in Q4 2023.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The CHMP recommendation will now be considered by the European Commission for marketing authorisation in the European Union. A final decision is expected soon - in Q4 2023.
Copyright (c) 2023 CercleFinance.com. All rights reserved.